1YTop 25% of the group
Rank 6 of 63 funds
Return +54.22%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 6No. 1 is SCBGENOME(E) +62.13%
TISCO Genomic Revolution Fund
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
TGENOME is a fund of funds that puts 98.70% into units of other funds, spread across several funds
This fundTGENOMEThis fund's manager selects the funds and adjusts their weights. The funds it holds also charge their own fees
All funds, as disclosed in the AMC fact sheet · The stocks these funds hold are shown below · This fund's performance therefore depends on the funds it holds
Twist Bioscience TWST8.89%
10x Genomics TXG7.84%Over the past year it was in the top 25% of its group; over 5 years it returned −11.74% per year (Bottom 25% of the group)
No. 1 is SCBGENOME(E) +62.13%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|---|
| +58.85% | −2.78% | +1.41% | −5.52% | +24.00% | +54.88% | +54.22% | +68.14% | −46.44% | −61.22% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan |
|---|
Largest drawdown in the selected period −84.43% Previous peak 20 Jan 2021 (NAV 10.4454) → Trough 8 Apr 2025 (NAV 1.6259) · Not back to the previous peak as of 3 Nov 2026
Currently −62.89% from the peak NAV of 10.4454 (20 Jan 2021)
Over 5 years, TGENOME returned -0.27 per unit of volatility, ranking 26 of 33 funds · The highest is FP HCARE-A (0.43)
กองทุนจะลงทุนในหน่วยลงทุนของกองทุนรวมตราสารทุนต่างประเทศ และ/หรือกองทุนรวมอีทีเอฟตราสารทุนต่างประเทศในภูมิภาคต่างๆ ทั่วโลก ที่มีนโยบายการลงทุนในตราสารทุนของบริษัทที่มีธุรกิจเกี่ยวข้องกับธีม Genomics Revolution ซึ่งเป็นบริษัทที่มุ่งเน้นและคาดว่าจะได้รับประโยชน์จากการยืดอายุขัย… Its largest holdings are ARK GENOMIC REVOLUTION ETF 78.20% · ISHARES GENOMICS IMMUNOLOGY AND HEALTHCARE ETF 10.85% · ISHARES BIOTECHNOLOGY ETF 9.66% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 13 Jan 2021, its NAV has fallen as much as −84.43% from its peak.
Actual total expense ratio (TER) 1.28% a year, against a ceiling of 5.00%. Management fee 1.07%. Front-end fee 1.25%. Back-end fee 0.00%. (Fact sheet 30 Sep 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
CRISPR Therapeutics CRSP4.10%
Absci ABSI3.96%
Natera NTRA3.92%
Illumina ILMN3.79%
Guardant Health GH3.61%
CareDx CDNA3.40%Twist Bioscience TWSTMakes synthetic DNA on silicon chips for drug and genetics research
10x Genomics TXGMakes single-cell analysis instruments and reagents for biology research
CRISPR Therapeutics CRSPHospitals, medicines and medical equipment
Absci ABSINatera NTRAIllumina ILMNHospitals, medicines and medical equipment
CareDx CDNABased on each ETF's actual share of the fund's value · Weighted by each fund held × the stocks that fund holds, covering 100% of the money invested in other funds. Uses each fund's top 10, so figures are a minimum · ARK Genomic Revolution as of 22 Oct 2026 · iShares Genomics Immunology and Healthcare as of 22 Oct 2026 · ISHARES BIOTECHNOLOGY as of 22 Oct 2026 · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +21.97% per year
No. 1 is FP HCARE-A +6.61% per year
| Feb |
|---|
| Mar |
|---|
| Apr |
|---|
| May |
|---|
| Jun |
|---|
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | +4.5 | +0.3 | −9.6 | +8.3 | +11.4 | +18.9 | −7.7 | +20.4 | +12.2 | −3.5 | −2.8 | · | +58.8* |
| 2025 | +10.4 | −6.6 | −13.6 | +3.7 | −4.8 | +11.7 | −1.1 | +3.5 | +10.2 | +11.4 | +2.2 | −6.4 | +18.0 |
| 2024 | −13.8 | +9.1 | −7.2 | −16.6 | +4.7 | −3.5 | +12.1 | −2.5 | −3.6 | −7.5 | +9.8 | −9.1 | −28.5 |
| 2023 | +17.2 | −9.5 | −1.5 | −3.2 | +7.1 | +6.4 | +8.7 | −12.6 | −12.1 | −15.7 | +16.6 | +19.6 | +13.2 |
| 2022 | −19.7 | −3.1 | −4.6 | −25.9 | −5.4 | −2.6 | +20.3 | −7.0 | −7.7 | +2.6 | −4.9 | −13.2 | −55.7 |
Minimum first purchase 1,000 THB, subsequent purchases 1,000 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+3
Hedged at the manager's discretion. As of 30 Sep 2026, 84.93% of the value of its foreign investments was hedged
